key: cord-0720562-htykaq8l
authors: Anastassopoulou, Cleo; Hatziantoniou, Sophia; Vlachopoulos, Charalambos; Spanakis, Nicholas; Tsioufis, Costas; Tsakris, Athanasios; Lazaros, George
title: Temporal relationship of myocarditis and pericarditis following COVID-19 vaccination: A pragmatic approach
date: 2022-04-15
journal: Int J Cardiol
DOI: 10.1016/j.ijcard.2022.04.024
sha: 78e7afb085149c6f17c420133fec3a410e71f08d
doc_id: 720562
cord_uid: htykaq8l

BACKGROUND: Complications following COVID-19 vaccination, particularly with mRNA vaccines, rarely include myocarditis and pericarditis. This work principally aimed at defining a realistic temporal relationship between vaccination and myocarditis/pericarditis development. METHODS: All relevant cases reported from week 52/2020 through week 41/2021 in the VAERS database were retrieved and analyzed for licensed vaccines. These included BNT162b2, mRNA-1273, and AD26.COV2·S. Incidence rates were calculated using the corresponding administered vaccine doses as denominators. Additionally, analyzed parameters included demographics, dose series, hospitalization length and outcome. RESULTS: Overall, 2016 myocarditis and 1380 pericarditis cases, (4.96/10(6) and 3.40/10(6) administered vaccine doses, respectively), were recorded. Most myocarditis cases occurred following BNT162b2 (5.60/10(6) doses) in males <30 years. Pericarditis affected predominantly males <40, both sexes >40 years, and was most common post AD26.COV2·S (4.78/10(6) doses). Hospitalization was required for 40.3% and 27.2% of myocarditis and pericarditis cases, respectively. A bimodal pattern was found for both myocarditis and pericarditis, with two peaks that coincided temporally, but were reversed in intensity. The first peak was recorded 1–3 days post-vaccination and was more pronounced in myocarditis, while the second was recorded 15–30 days post-vaccination and was more intense in pericarditis. CONCLUSIONS: Myocarditis/pericarditis after COVID-19 vaccination is rare and depicts a bimodal pattern.

following BNT162b2 (5.60/10 6 doses) in males <30 years. Pericarditis affected predominantly males <40, both sexes >40 years, and was most common post AD26.COV2.S (4.78/10 6 doses). Hospitalization was required for 40.3% and 27.2% of myocarditis and pericarditis cases, respectively. A bimodal pattern was found for both myocarditis and pericarditis, with two peaks that coincided temporally, but were reversed in intensity. The first peak was recorded 1-3 days post-vaccination and was more pronounced in myocarditis, while the second was recorded 15-30 days post-vaccination and was more intense in pericarditis.

Myocarditis/pericarditis after COVID-19 vaccination is rare and depicts a bimodal pattern.

Keywords: COVID-19 vaccines; myocarditis; pericarditis; onset interval; VAERS The beginning of the third pandemic year of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) finds humanity still largely depending on vaccines to control coronavirus disease 2019 (COVID-19). Myocarditis and pericarditis are rare, but concerning complications following vaccination against COVID-19, particularly with the novel mRNAbased vaccines [1] [2] [3] [4] . A limitation in the estimation of the actual incidence of such complications is the time interval between vaccination and cardiac inflammation symptoms onset that has been reported to vary widely, ranging from 0 to 144 days [5] .

To define a realistic temporal relationship between vaccination and myocarditis or pericarditis development, we analyzed all relevant cases recorded in the Vaccine Adverse vaccination reported by healthcare professionals, vaccine manufacturers and patients [5] . As a passive reporting system, VAERS is subject to misreporting biases. However, the risk is minimized since reported adverse events undergo internal evaluation, including detection and merge of duplicated cases [5, 6] . We used the public database of VAERS that is coded using the MedDRA system. The Brighton Collaboration definitions are used only for cases for which additional follow-up, including collection of medical records, is done by CDC and FDA investigators [5] . were retrieved from the public database "Our World in Data" and used as denominators to estimate incidence rates per 10 6 doses for each vaccine [7] . The mean myocarditis and pericarditis rates for these COVID-19 vaccines were calculated by summing all myocarditis and all pericarditis cases post COVID-19 vaccination reported to VAERS for all COVID-19 vaccines, and then dividing by the corresponding total number of administered doses.

Analyzed parameters included vaccination (vaccine manufacturer, dose series), event (onset interval, hospitalization days, category), and demographic information of cases (age, sex).

A total of 406,570,875 doses of COVID-19 vaccines were administered in the US from 17.5%, 10.9%, and 9.3% that required 2, 1, and 3 days, respectively. Events leading to permanent disability were rare (2.1% for myocarditis and 2.5% for pericarditis) and deaths even rarer, but higher for myocarditis than pericarditis (1.0% vs. 0.2%, respectively). In six myocarditis and three pericarditis cases, existing hospitalization was prolonged. The relatively low hospitalization rates that were found may not be surprising given that most vaccine-related myocarditis and pericarditis cases are reported to be mild and self-limited [8, 9] .

Data analysis revealed a bimodal pattern for both myocarditis and pericarditis with two peaks that coincided temporally, but which were reversed in intensity as depicted by the relative percentages of recorded events (Fig.1 ). The first peak (1-3 days post vaccination) was more pronounced in myocarditis (~18-19% of cases each day vs. 10-12.5% for pericarditis cases), whereas the second peak (15-30 days post vaccination) was more intense in pericarditis (accounting for 14% compared to 9% for myocarditis cases). Intriguingly, this bimodal pattern for both myocarditis and pericarditis was common for all COVID-19 vaccines, irrespectively of platform (mRNA-or vector-based). Does this imply that this bimodal pattern stems from the pathophysiology of the induced heart inflammation?

We hypothesize that the first peak could represent a rapid immune reaction to extra RNA species inoculated with mRNA vaccines, or due to acute toxicity to the high inoculates of recombinant replication-incompetent adenovirus vector encoding the SARS-CoV-2 spike protein of vectored vaccines, as we have previously described [3, 4] . The second peak could be attributed to delayed immune responses to mRNA produced by the vaccinees' cells.

rare cardiac adverse events associated with COVID-19 vaccination reported an increase in the risk of myocarditis within a week of receiving the first dose of both (simian) adenovirus and mRNA vaccines, and a higher risk after the second dose of both mRNA vaccines; an increase in the risk of pericarditis was only found in the 1-28 days following a second dose of the mRNA-1273 vaccine in this study [9] . Real-world data indeed show increased rates for myocarditis and pericarditis after COVID-19 vaccines: In the pre-vaccine period, the mean monthly number of myocarditis or myopericarditis cases was reported to be 16.9 compared to 27.3 in the vaccine period (P < .001), while the mean numbers of pericarditis cases were 49.1 and 78.8, respectively, during the same periods (P < .001) [8] .

The use of real-life data retrieved from VAERS, one of the largest reporting systems on vaccine-associated adverse events globally, is a strength of the current study. VAERS complements other vaccine safety monitoring systems in the US, including v-safe and the Vaccine Safety Datalink [13] . The lack of an accurate denominator of vaccine doses administered in this system which cannot generally determine cause and effect, is a potential limitation. In addition, the onset interval was unknown for 8.4% and 5.0% of myocarditis and pericarditis cases, respectively. Other limitations, pertaining principally to the usage of such a passive reporting system that can rapidly detect a potential safety problem, possibly include reporting bias which could under-or over-estimate true heart inflammation rates. However, in our view, this was likely not the case given the enhanced COVID-19 vaccine safety scrutiny as mass vaccination strategies were implemented around the world under the attention of mass media. The agreement of our results to the findings of other studies offers 

Severe COVID-19 vaccine associated myocarditis: Zebra or unicorn?

Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients

The Novel Platform of mRNA COVID-19 Vaccines and Myocarditis: Clues into the Potential Underlying Mechanism

A case series of acute pericarditis following COVID-19 vaccination in the context of recent reports from Europe and the United States

Vaccine Adverse Event Reporting System

Probabilistic record linkage of structured and unstructured data to identify duplicate cases in spontaneous adverse event reporting systems

Coronavirus Pandemic (COVID-19)

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection

Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From

Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military

Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

The significance of COVID-19-associated myocardial injury: how overinterpretation of scientific findings can fuel media sensationalism and spread misinformation

* For corresponding reported events (n=3,589 for myocarditis and n=2,529 for pericarditis)